Coffee Intake and Neurocognitive Performance in HIV/HCV Coinfected Patients (ANRS CO13 HEPAVIH)

Saskia Antwerpes1, Camelia Protopopescu1,2, Philippe Morlat3

  • 1Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, 13385 Marseille, France.

Nutrients
|August 23, 2020
PubMed

Insights

Regular coffee intake may preserve cognitive function in individuals coinfected with HIV and HCV. Elevated coffee consumption showed positive associations with verbal fluency, psychomotor speed, and executive functioning in this population.

Area of Science:

  • Neuroscience
  • Hepatology
  • Infectious Diseases

Background:

  • Coffee is a widely consumed beverage with known neuroprotective properties.
  • HIV-HCV coinfection accelerates aging and causes cognitive impairment, impacting quality of life and treatment adherence.
  • Understanding factors that support cognitive health in this population is crucial.

Purpose of the Study:

  • To investigate the association between regular coffee intake and neurocognitive performance (NCP) in patients coinfected with HIV and HCV.
  • To determine if elevated coffee intake (ECI) is linked to better cognitive outcomes in this specific cohort.

Main Methods:

  • Analysis of data from 139 HIV-HCV coinfected patients from the ANRS CO13 HEPAVIH cohort and HEPAVIH-Psy survey.
  • Linear regression models were employed, adjusting for sociodemographic, clinical, and socio-behavioral factors.
  • Neurocognitive performance was assessed across various domains including verbal fluency, psychomotor speed, and executive functioning.

Main Results:

  • A significant, positive association was found between elevated coffee intake (≥3 cups/day) and enhanced NCP.
  • Specifically, ECI correlated with improvements in verbal fluency, psychomotor speed (coding), and executive functioning.
  • No other factors showed such a consistent positive link to cognitive performance in this cohort.

Conclusions:

  • Elevated coffee intake may play a protective role in maintaining neurocognitive functioning in individuals coinfected with HIV and HCV.
  • Further research could explore the mechanisms behind coffee's neuroprotective effects in this vulnerable population.
  • Findings suggest a potential lifestyle intervention to support cognitive health in HIV-HCV coinfected patients.

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
71
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
627
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
851
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
106
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
104
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
136